PE20240776A1 - Compuestos terapeuticos y procedimientos - Google Patents
Compuestos terapeuticos y procedimientosInfo
- Publication number
- PE20240776A1 PE20240776A1 PE2024000068A PE2024000068A PE20240776A1 PE 20240776 A1 PE20240776 A1 PE 20240776A1 PE 2024000068 A PE2024000068 A PE 2024000068A PE 2024000068 A PE2024000068 A PE 2024000068A PE 20240776 A1 PE20240776 A1 PE 20240776A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- groups
- halo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000012435 Phosphofructokinase-1 Human genes 0.000 abstract 1
- 108010022684 Phosphofructokinase-1 Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002414 glycolytic effect Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 hydroxy, carboxy Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula (I) o un profarmaco de este, o una sal farmaceuticamente aceptable de este, asi como composiciones farmaceuticas y procedimientos para tratar enfermedades asociadas con la actividad de la enzima glucolitica fosfofructocinasa-1 de tipo hepatica, tales como el cancer, la diabetes, la sepsis y el choque septico. En particular, la presente invencion se refiere a un compuesto de formula (I) o un profarmaco de este, o una sal farmaceuticamente aceptable de este, en donde: R1 es -NRaRb o un heteroarilo de 5-10 miembros que esta opcionalmente sustituido con uno o mas grupos Rc; R2 es un arilo de 6-10 miembros que esta opcionalmente sustituido con uno o mas grupos Rr; o R2 es un heteroarilo de 5-10 miembros que esta opcionalmente sustituido con uno o mas grupos Rs; o R2 es un heterociclo de 3-10 miembros que esta opcionalmente sustituido con uno o mas grupos Rz; Ra es alquil (C1-C6), cicloalquil (C3-C6), alquenil (C2-C6), entre otros; Rb es H o alquil (C1-C6); cada Rc es alquil (C1-C6), cicloalquil (C3-C6), cicloalquil (C3-C6)alquil (C1-C6), entre otros, en donde cada alquil (C1-C6), cicloalquil (C3-C6), cicloalquil (C3-C6)alquil (C1-C6), entre otros, esta opcionalmente sustituido con uno o mas grupos seleccionados independientemente del grupo que consiste en halo, hidroxi, carboxi y ciano; cada Rr se selecciona independientemente del grupo que consiste en halo, hidroxi, ciano, entre otros; cada Rs se selecciona independientemente del grupo que consiste en halo, ciano, entre otros; y cada Rz se selecciona independientemente del grupo que consiste en oxo, halo, hidroxi, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222288P | 2021-07-15 | 2021-07-15 | |
| PCT/US2022/036829 WO2023287793A1 (en) | 2021-07-15 | 2022-07-12 | Therapeutic compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240776A1 true PE20240776A1 (es) | 2024-04-17 |
Family
ID=84919638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000068A PE20240776A1 (es) | 2021-07-15 | 2022-07-12 | Compuestos terapeuticos y procedimientos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12006331B2 (es) |
| EP (1) | EP4370130A4 (es) |
| JP (1) | JP2024527604A (es) |
| KR (1) | KR20240036571A (es) |
| CN (1) | CN117642170A (es) |
| AR (1) | AR126470A1 (es) |
| AU (1) | AU2022309856A1 (es) |
| CA (1) | CA3226225A1 (es) |
| CL (1) | CL2024000114A1 (es) |
| CO (1) | CO2024001017A2 (es) |
| CR (1) | CR20240016A (es) |
| IL (1) | IL309878A (es) |
| MX (1) | MX2024000610A (es) |
| PE (1) | PE20240776A1 (es) |
| TW (1) | TW202317586A (es) |
| WO (1) | WO2023287793A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240776A1 (es) | 2021-07-15 | 2024-04-17 | Genentech Inc | Compuestos terapeuticos y procedimientos |
| WO2025082533A1 (zh) * | 2023-10-21 | 2025-04-24 | 上海轶诺药业有限公司 | 一种稠环化合物及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039475A1 (es) | 2002-05-01 | 2005-02-23 | Wyeth Corp | 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa |
| US20070232582A1 (en) | 2004-04-28 | 2007-10-04 | Wyeth Holdings Corporation | 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors |
| EP3813805A4 (en) | 2018-06-27 | 2021-08-25 | Children's Medical Center Corporation | COMPOUNDS FOR INHIBITION OF INFLAMMATION |
| EP3833345B1 (en) | 2018-08-07 | 2024-07-17 | Kemijski Institut | Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells |
| PE20240776A1 (es) | 2021-07-15 | 2024-04-17 | Genentech Inc | Compuestos terapeuticos y procedimientos |
-
2022
- 2022-07-12 PE PE2024000068A patent/PE20240776A1/es unknown
- 2022-07-12 CR CR20240016A patent/CR20240016A/es unknown
- 2022-07-12 US US17/862,963 patent/US12006331B2/en active Active
- 2022-07-12 IL IL309878A patent/IL309878A/en unknown
- 2022-07-12 MX MX2024000610A patent/MX2024000610A/es unknown
- 2022-07-12 JP JP2024501696A patent/JP2024527604A/ja active Pending
- 2022-07-12 KR KR1020247002069A patent/KR20240036571A/ko active Pending
- 2022-07-12 CN CN202280049669.2A patent/CN117642170A/zh active Pending
- 2022-07-12 CA CA3226225A patent/CA3226225A1/en active Pending
- 2022-07-12 WO PCT/US2022/036829 patent/WO2023287793A1/en not_active Ceased
- 2022-07-12 EP EP22842759.7A patent/EP4370130A4/en active Pending
- 2022-07-12 AU AU2022309856A patent/AU2022309856A1/en active Pending
- 2022-07-15 AR ARP220101868A patent/AR126470A1/es unknown
- 2022-07-15 TW TW111126584A patent/TW202317586A/zh unknown
-
2024
- 2024-01-12 CL CL2024000114A patent/CL2024000114A1/es unknown
- 2024-01-30 CO CONC2024/0001017A patent/CO2024001017A2/es unknown
- 2024-05-08 US US18/657,963 patent/US12459957B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4370130A4 (en) | 2025-06-11 |
| US20250109142A1 (en) | 2025-04-03 |
| KR20240036571A (ko) | 2024-03-20 |
| JP2024527604A (ja) | 2024-07-25 |
| AR126470A1 (es) | 2023-10-11 |
| TW202317586A (zh) | 2023-05-01 |
| CN117642170A (zh) | 2024-03-01 |
| CO2024001017A2 (es) | 2024-03-07 |
| MX2024000610A (es) | 2024-02-02 |
| CA3226225A1 (en) | 2023-01-19 |
| AU2022309856A1 (en) | 2024-01-18 |
| CR20240016A (es) | 2024-02-13 |
| EP4370130A1 (en) | 2024-05-22 |
| US20230119740A1 (en) | 2023-04-20 |
| WO2023287793A1 (en) | 2023-01-19 |
| US12459957B2 (en) | 2025-11-04 |
| US12006331B2 (en) | 2024-06-11 |
| IL309878A (en) | 2024-03-01 |
| CL2024000114A1 (es) | 2024-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| CO2024017733A2 (es) | Inhibidores macrocíclicos de kras para el tratamiento de cáncer | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| PE20240769A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| PE20250664A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| PE20240776A1 (es) | Compuestos terapeuticos y procedimientos | |
| ECSP21044843A (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| CL2022001887A1 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| PE20211447A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas | |
| PE20230601A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| PE20250833A1 (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| MX2021009206A (es) | Terapias contra el cancer. |